All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
Information source: Shandong University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Purpura; Idiopathic Thrombocytopenic Purpura
Intervention: All-Trans Retinoid Acid(ATRA) (Drug); Dexamethasone (Drug)
Phase: Phase 3
Status: Recruiting
Sponsored by: Shandong University Official(s) and/or principal investigator(s): Ming Hou, Dr, Principal Investigator, Affiliation: Shandong University
Overall contact: Ming Hou, Dr, Phone: +86-531-82169114, Ext: 9879, Email: houming@medmail.com.cn
Summary
The project was undertaking by Qilu Hospital of Shandong University in China. In order to
report the efficacy and safety of All-Trans Retinoic Acid (ATRA) combining with High-dose
Dexamethasone for the treatment of adults with primary immune thrombocytopenia (ITP),
compared to conventional high-dose dexamethasone therapy.
Clinical Details
Official title: Clinical Study on All-Trans Retinoic Acid (ATRA) Combining High-dose Dexamethasone Versus High-dose Dexamethasone Alone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Platelet count
Detailed description:
The investigators are undertaking a parallel group, randomised controlled trial of 80
primary ITP adult patients from Qilu Hospital of Shandong University in China. One part of
the participants are randomly selected to receive All-Trans Retinoic Acid(10mg tablet by
mouth every 8 hours a day for 12 consecutive weeks, combining with dexamethasone (given
orally at a dose of 40 mg per day for 4 days, the others are selected to receive high-dose
of dexamethasone treatment (given orally at a dose of 40 mg daily for 4 days). Patients were
monitored every 1 to 3 days at the first two weeks and every 1 to 4 weeks afterwards for
platelet counts, and were monitored every 1 month for transaminitis and other side effects
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Meet the diagnostic criteria for immune thrombocytopenia.
2. Untreated hospitalized patients, may be male or female, between the ages of 18 ~ 80
years.
3. To show a platelet count < 30×10^9/L, and with bleeding manifestations.
4. Eastern Cooperative Oncology Group(ECOG)performance status ≤ 2.
5. Willing and able to sign written informed consent
Exclusion Criteria:
1. Received chemotherapy or anticoagulants or other drugs affecting the platelet counts
within 3 months before the screening visit.
2. Received high-dose steroids or [2] intravenous immunoglobulin transfusion(IVIG)in the
3 weeks prior to the start of the study.
3. Current HIV infection or hepatitis B virus or hepatitis C virus infections. Severe
medical condition (lung, hepatic or renal disorder) other than ITP. 4. Unstable or
uncontrolled disease or condition related to or impacting cardiac function (e. g.,
unstable angina, congestive heart failure, uncontrolled hypertension or cardiac
arrhythmia)
5. Female patients who are nursing or pregnant, who may be pregnant, or who contemplate
pregnancy during the study period.
6. Have a known diagnosis of other autoimmune diseases, established in the medical history
and laboratory findings with positive results for the determination of antinuclear
antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test.
7. Patients who are deemed unsuitable for the study by the investigator.
Locations and Contacts
Ming Hou, Dr, Phone: +86-531-82169114, Ext: 9879, Email: houming@medmail.com.cn
Qilu Hospital, Shandong University, Jinan, Shandong 250000, China; Recruiting Ming Hou, Dr, Phone: +86-531-82169114, Ext: 9879, Email: houming@medmail.com.cn
Additional Information
Related publications: Tóth K, Sarang Z, Scholtz B, Brázda P, Ghyselinck N, Chambon P, Fésüs L, Szondy Z. Retinoids enhance glucocorticoid-induced apoptosis of T cells by facilitating glucocorticoid receptor-mediated transcription. Cell Death Differ. 2011 May;18(5):783-92. doi: 10.1038/cdd.2010.136. Epub 2010 Nov 12. Tancini G, Marchini S. Adriamycin plus cyclophosphamide in advanced bronchial carcinoma. Tumori. 1976 Jul-Aug;62(4):373-5. Tosi P, Pellacani A, Visani G, Ottaviani E, Ronconi S, Zamagni E, Benni M, Cavo M, Tura S. In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells. Eur J Haematol. 1999 Mar;62(3):143-8. Chen YH, Desai P, Shiao RT, Lavelle D, Haleem A, Chen J. Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: synergy through modulation of interleukin-6 autocrine loop at multiple sites. Blood. 1996 Jan 1;87(1):314-23.
Starting date: February 2013
Last updated: June 17, 2013
|